Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

MiNK Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, AUG. 13, 2026 (GLOBE NEWSWIRE) -- MINK THERAPEUTICS, INC. (NASDAQ: INKT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING OFF-THE-SHELF ALLOGENEIC INVARIANT NATURAL KILLER T (INKT) CELL THERAPIES FOR CANCER AND IMMUNE DISORDERS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, AND PROVIDED AN UPDATE ON THE CLINICAL ADVANCEMENT OF ITS LEAD CANDIDATE, AGENT-797.

MINK THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND REPORTS OBSERVATIONS FROM RANDOMIZED PHASE 2 TRIAL OF AGENT-797 IN ACUTE LUNG INJURY

NEW YORK, AUG. 06, 2026 (GLOBE NEWSWIRE) -- MINK THERAPEUTICS, INC. (NASDAQ: INKT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING ALLOGENEIC INVARIANT NATURAL KILLER T (INKT) CELL THERAPIES TO TREAT CANCER AND IMMUNE DISORDERS, TODAY ANNOUNCED THAT IT WILL REPORT FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, BEFORE THE MARKET OPENS ON THURSDAY, AUGUST 13, 2026. THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST AT 8:30 AM ET THAT MORNING TO REVIEW FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE FOCUSED ON THE CLINICAL ADVANCEMENT OF AGENT-797, MINK'S OFF-THE-SHELF ALLOGENEIC INKT CELL THERAPY, IN ACUTE LUNG INJURY.

MINK THERAPEUTICS TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS, PROVIDE CLINICAL UPDATES ON AGENT-797 IN LUNG INJURY, AND HIGHLIGHT IMPORTANT BUSINESS UPDATES

MiNK Therapeutics, Inc.

INKT

Price

Financial Reports

No items found.

Press Releases

MiNK Therapeutics, Inc.

INKT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

INKT